669 Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer

BackgroundTreatment options for patients with platinum resistant ovarian cancer [PROC] are limited. Immune checkpoint inhibitors (ICI) have limited activity in PROC, therefore clinical studies evaluating novel therapies are urgently needed. We have previously reported durable and a complete response with COM701 +/- BMS986207 + nivolumab.1 COM701 is a novel, 1stin-class ICI binding to PVRIG, that leads to activation of T-cells. BMS-986207 is an ICI of TIGIT. We report longer term follow-up showing continued durable responses in patients with PROC treated with a triple immunotherapy combination blocking the DNAM-1 axis with COM701 + BMS-986207 + nivolumab (NCT04570839).MethodsWe enrolled 20 patients with PROC treated with COM701 20 mg/kg + BMS-986207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives were safety/tolerability; secondary objective of preliminary antitumor activity. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard treatments. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-(L)-1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0.ResultsNo new safety signals are reported. The combination is well tolerated. There were 4/20 [20%] patients with confirmed PR and 5 pts with SD with a DCR [CR+PR+SD] 9/20 [45%], no CRs. Median [med] age 61yr, med number of prior lines of therapy - 4 [range 1–10]. Histology of patients with PR – high grade serous adenocarcinoma [3 pts], clear cell histology [1 pt]. Three pts continue study treatment at 449, 428 and 477 days, 1 pt with high grade serous adenocarcinoma was on study treatment for 222 days.ConclusionsContinued durable confirmed partial responses by blocking the DNAM-1 axis with the combination of COM701 + BMS-986207 + nivolumab in pts with heavily pre-treated PROC. Additional translational data will be presented at the conference. Data extract 06/09/2023.AcknowledgementsWe thank the patients for participating in this clinical trial and their families, the investigators and their staff at the clinical trial sites; Study Sponsor Compugen Ltd in collaboration with Bristol Myers Squibb; Danae Hudson, Amanda Harp, Compugen USA Inc for clinical operations oversight of the studyTrial RegistrationNCT04570839.ReferenceMoroney JA, Yeku O, et al. Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant